AI Article Synopsis
- This study compared the analytical sensitivity and clinical performance of two SARS-CoV-2 testing methods: the Cobas SARS-CoV-2 Test (Cobas 6800 system) and the Cobas SARS-CoV-2 & Flu A/B Test (cobas Liat system).
- The Cobas Liat system showed better sensitivity with a lower detection limit (12.5-25 copies/mL) compared to the Cobas 6800 system (25-50 copies/mL).
- Both tests demonstrated high accuracy, with the Cobas 6800 showing 89.36% positive and 98.82% negative percent agreement, making them reliable for early virus detection and decision-making during the COVID-19
Article Abstract
Objectives: This study examined analytical sensitivity, specificity, and the clinical performance in detecting SARS-CoV-2 of the Cobas SARS-CoV-2 Test based on the high-throughput Cobas 6800 system and the Cobas SARS-CoV-2 & Flu A/B Test based on the point-of-care cobas Liat system.
Methods: The commercial reagents containing SARS-CoV-2 RNA subgenomes were diluted for assessing the sensitivity of the RT-qPCR assay. 385 nasopharyngeal swab specimens taken from contacts of COVID-19 cases were tested for the SARS-CoV-2 detection with both Cobas SARS-CoV-2 Tests.
Results: In analytical sensitivity assays, the Cobas SARS-CoV-2 & Flu A/B Test on the Liat system had a lower limit of detection (12.5-25 copies/mL) than the cobas SARS-CoV-2 Test on the cobas 6800 system (25-50 copies/mL). In clinical performance assays, the cobas SARS-CoV-2 Test demonstrated 89.36% (42 out of 47) PPA (positive percent agreement) and 98.82% (334 out of 338) NPA (negative percent agreement) compared to the results of the Cobas SARS-CoV-2 & Flu A/B test. Among five discordant specimens, four had the positive result of the cobas SARS-CoV-2 test, but the negative result of the cobas SARS-CoV-2 & Flu A/B Test. Moreover, these discordant specimens had the Ct values of greater than 33 for the cobas SARS-CoV-2 Test, implying a very small number of virions in the samples. Remarkably, four specimens with a presumptive positive result of the cobas SARS-CoV-2 test had been confirmed by the Cobas SARS-CoV-2 & Flu A/B Test. Next, the scatter plots of the Ct values showed a highly positive correlation between cobas SARS-CoV-2 & Flu A/B Test and the cobas SARS-CoV-2 Test (R-squared value = 0.954-0.962).
Conclusions: Both SARS-CoV2 tests of the cobas 6800 and Liat systems produce reliable high throughput and point-of-care assays respectively for the early virus detection and the personal care decision-making during COVID-19 pandemic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236719 | PMC |
| http://dx.doi.org/10.37796/2211-8039.1334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of SARS-CoV-2 RNA detection in different types of clinical specimens among suspected COVID-19 patients in Addis Ababa, Ethiopia.
Virusdisease
December 2024
Microbiology, Immunology and Parasitology, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Unlabelled: Although nasopharyngeal swabs (NPSs) are superior to saliva specimens, saliva can be used as an alternative specimen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. Moreover, studies have reported contradicting findings on whether SARS-CoV-2 can be detected in urine or not. Thus, we aimed to evaluate the diagnostic utility of NPSs, saliva and urine specimens in suspected COVID-19 patients.
View Article and Find Full Text PDFComparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
Front Immunol
November 2024
Center for Clinical and Nutritional Chemistry, School of Chemistry, University of the Punjab, Lahore, Pakistan.
Article Synopsis
- The study investigates the effects of heterologous (different) and homologous (same) COVID-19 vaccine booster doses in healthy adults in Pakistan, focusing on immune responses nine months post-vaccination.
- A total of 173 participants aged 18-25 received either Sinopharm BBIBP-CorV or Pfizer-BioNTech vaccines, with antibody levels measured to compare immune responses.
- Results show that the Pfizer group had significantly higher IgG antibody levels compared to the Sinopharm group, suggesting that a third Pfizer dose after two Sinopharm doses enhances overall immune response, with no significant differences between genders.
The potential relationship between EasyNAT system Tt values and Cobas z480 Ct values in the detection of SARS-Cov-2.
Pract Lab Med
November 2024
Department of Clinical Laboratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Article Synopsis
- - The study investigates the relationship between EasyNAT system time threshold (Tt) values and Cobas z480 cycle threshold (Ct) values in detecting SARS-CoV-2 from oropharyngeal swabs, using retrospective data from a clinical lab.
- - A total of 277 EasyNAT-positive samples showed a 100% concordance with Cobas z480, indicating that as Tt values increased, the mean and maximum Ct values for specific viral genes also increased.
- - The findings suggest that the EasyNAT system is a reliable, efficient alternative for SARS-CoV-2 detection in hospitals, particularly in facilities lacking advanced PCR technology, with Tt values of ≤6 serving as a reference for
Assessment of DNA/RNA Defend Pro: An Inactivating Sample Collection Buffer for Enhanced Stability, Extraction-Free PCR, and Rapid Antigen Testing of Nasopharyngeal Swab Samples.
Int J Mol Sci
August 2024
InActiv Blue, Industriepark Oost 2A, 8730 Beernem, Belgium.
Article Synopsis
- The study evaluated the DNA/RNA Defend Pro (DRDP) collection buffer for its ability to inactivate and stabilize patient samples, while assessing its effectiveness for extraction-free PCR and quick antigen testing.
- Out of 95 nasopharyngeal swab samples tested for various viruses, the results confirmed the presence of viral targets, showing that DRDP maintained sample stability and compatibility with testing methods including direct RT-qPCR.
- DRDP demonstrated excellent RNA stability for key viruses over a week at various temperatures, making it a reliable option for enhancing diagnostic efficiency in challenging testing environments.
Detection and comparison of SARS-CoV-2 antibody produced in naturally infected patients and vaccinated individuals in Addis Ababa, Ethiopia: multicenter cross-sectional study.
Virol J
August 2024
Department of Microbiology, Immunology and Parasitology, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Article Synopsis
- A study was conducted in Ethiopia to compare antibody levels against SARS-CoV-2 in 355 naturally infected and 355 vaccinated individuals between November 2022 and April 2023.
- The results showed that while both groups produced anti-S antibodies, vaccinated individuals had significantly higher levels compared to those who were naturally infected.
- Factors such as youth, hypertension, and diabetes were linked to lower anti-S antibody levels among participants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!